Efficacy and safety of modified electroconvulsive therapy for the refractory depression in older patients

2019 ◽  
Author(s):  
Xue Jiang ◽  
Qin Xie ◽  
Lian-Zhong Liu ◽  
Bao-Liang Zhong ◽  
Liang Si ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Older Patients ◽  
Depression Scale ◽  
Pressure Rise ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Refractory Depression ◽  
Immediate Memory ◽  
Modified Electroconvulsive Therapy

Abstract Background: To explore the clinical efficacy and safety of modified electroconvulsive therapy (MECT) in the treatment of elderly patients with refractory depression. Methods : A total of 43 older patients (18 male and 25 female) with refractory depression were enrolled in our study from March 2014 to February 2015, with the average age of 65±4.8 years old. Modified electroconvulsive therapy (MECT) was performed in these patients after physical examinations and anesthesia procedures. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to assess the efficacy of MECT, and Wechsler Memory Scale (WMS) and mini mental state examination (MMSE) were used to evaluate the memory ability and cognitive function. The preoperative, intraoperative and postoperative care were conducted in patients accompanied by physical diseases. Results: The rate of efficacy was calculated as 67.44% after 4 weeks of MECT treatment. Our results showed HAMA and HAMD scores after 2 weeks of MECT treatment were significantly lower than that before treatment (P<0.05), and the differences were more significant after 4 weeks of MECT treatment (P<0.01). Compared with before treatment, the scores of memory quotient and immediate memory of WMS decreased significantly after 1 week of treatment (P<0.05). However, these events were not be presented with the progress of treatment, except for after 2 weeks of treatment. Our results demonstrated that compared with before treatment, the scores of MMSE significantly increased significantly after 4 weeks of treatment (P<0.05). There were no serious adverse events in all patients, including cardiovascular and cerebrovascular events. Among them, 7 patients had transient blood pressure rise and slight headache, which were relieved spontaneously after resting. Conclusion: MECT is an effective, well tolerated and safe method for the treatment of older patients with refractory depression, which is temporary and reversible for cognitive impairment. MECT can be recommended for the treatment of these patients after conducting effective risk control of comorbid somatic diseases.

scholarly journals Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Yi-Fan Li ◽  
Hui-Min Hu ◽  
Bo-Ning Wang ◽  
Yi Zhang ◽  
Xing Liu ◽  
...  
Keyword(s):  
Treatment Group ◽  
Migraine Attack ◽  
Controlled Trial ◽  
Depression Scale ◽  
Control Group ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Attack Frequency ◽  
Double Blind ◽  
Double Blind Placebo

Objective. To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. Method. This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). Results. A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group ( P < 0.001 ). No severe adverse events were observed in this trial. Conclusion. Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile.

scholarly journals Efficacy and safety of Xiaoyao pills for mild to moderate depression: study protocol for a randomized controlled trial

Trials ◽  
2022 ◽  
Vol 23 (1) ◽  
Author(s):  
Zhe Xue ◽  
Zhen Huang ◽  
Shu-li Cheng ◽  
Xi-hong Wang ◽  
Xuan Zhou ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Adverse Reactions ◽  
Controlled Trial ◽  
Depression Scale ◽  
Secondary Outcome ◽  
Controlled Clinical Trial ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Moderate Depression

Abstract Background Depression is one of the most frequent and severe psychiatric conditions. Many chemical drugs to treat depression are associated with adverse reactions and have shortcomings. Traditional Chinese medicine is of great significance in the prevention and treatment of depression. Xiaoyao pills has achieved good results in clinical application, which has the advantages of quick effect and no obvious adverse reactions. The aim of our study is to evaluate the efficacy and safety of Xiaoyao pills on mild to moderate depression patients. Methods This study is a multi-centre, double-blinded, randomized and placebo-controlled clinical trial. A total of 108 participants are assigned to three groups: Xiaoyao pill group taking Xiaoyao pills twice daily for 4 weeks, placebo group taking placebos twice daily for 4 weeks and normal group without taking any drug. The primary and secondary outcome measures are the Hamilton Depression Scale (HAMD) and Traditional Chinese Medicine (TCM) Syndrome Scale. The assessment is at baseline (before treatment initiation), 1 week, 2 weeks 4 weeks after the first treatment. Exploratory outcome is also assessed to explore the mechanism of Xiaoyao pills at baseline and 4 weeks. Discussion The results from this study will provide clinical evidence on the efficacy and safety of Xiaoyao pills in patients with mild to moderate depression with syndrome of liver stagnation and spleen deficiency. Trial registration ClinicalTrials.gov ISRCTN12746343. Registered on September 25, 2020.

scholarly journals Clinical Studies on Treatment of Earthquake-Caused Posttraumatic Stress Disorder Using Electroacupuncture

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Yu Wang ◽  
You-ping Hu ◽  
Wen-chun Wang ◽  
Ri-zhao Pang ◽  
An-ren Zhang
Keyword(s):  
Depression Scale ◽  
Treated Group ◽  
Acupuncture Group ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Symptom Scale ◽  
Significant Efficacy ◽  
Hamilton Anxiety Scale ◽  
Ptsd Scale ◽  
Better Than

The objective of this study was to assess the efficacy and safety of electroacupuncture in 138 patients with earthquake-caused PTSD using Randomized Controlled Trials (RCTs). 138 cases enrolled were randomly assigned to an electro-acupuncture group and a paroxetine group. The electro-acupuncture group was treated by scalp electro-acupuncture on Baihui (GV 20), Sishencong (EX-HN 1), Shenting (GV 24), and Fengchi (GB 20), and the paroxetine group was treated with simple oral administration of paroxetine. The efficacy and safety of the electro-acupuncture on treatment of 69 PTSD patients were evaluated using Clinician-Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and Treatment Emergent Symptom Scale (TESS) according to clinical data. The total scores of CAPS, HAMD, and HAMA in the two groups after treatment showed significant efficacy compared to those before treatment. The comparison of reduction in the scores of CAPS, HAMD, and HAMA between the two groups suggested that the efficacy in the treated group was better than that in the paroxetine group. The present study suggested that the electro-acupuncture and paroxetine groups have significant changes in test PTSD, but the electro-acupuncture 2 group was more significant.

scholarly journals Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial

2021 ◽  
Vol 12 ◽  
Author(s):  
Jiaojiao Zhou ◽  
Xu Chen ◽  
Le Xiao ◽  
Jingjing Zhou ◽  
Lei Feng ◽  
...  
Keyword(s):  
Placebo Group ◽  
Controlled Trial ◽  
Depression Scale ◽  
Cordyceps Militaris ◽  
Secondary Outcome ◽  
Controlled Study ◽  
Depression Symptom ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Double Blind

Background: Insomnia is a common clinical manifestation in patients with depression. Insomnia is not only a depression symptom but also an independent risk factor for recurrence. Cordyceps militaris (C. militaris) is thought to have the potential to treat insomnia. This study aimed to examine the efficacy and safety of duloxetine with C. militaris in improving sleep symptoms in patients with depression.Methods: This study was a single-center, randomized, double-blind, placebo-controlled study that recruited outpatients admitted to Beijing Anding hospital from January 2018 to January 2019. Major depressive disorder (MDD) with insomnia was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and Mini-International Neuropsychiatric Interview (M.I.N.I.). Eligible subjects will be randomly assigned to two treatment groups in a 1:1 ratio, and receive treatment and follow-up of about 6 weeks of duloxetine plus Cordyceps militaris or placebo, respectively. The severity of depression and insomnia was evaluated at baseline and at 1, 2, 4, and 6 weeks using the 17-item Hamilton Depression Scale (HAMD-17) and Athens Insomnia Scale (AIS).Results: A total of 59 subjects were included in the study (31 in the placebo group and 28 in the C. militaris group). 11 (18.6%) participants withdrew during the study period, 5 (17.9%) in the C. militaris group, and 6 (19.3%) in the placebo group. Depressive and sleep symptoms in all patients reduced over time. We found that the total scores of AIS and its subscales decreased more in the placebo group compared to the C. militaris group (p &lt; 0.05). Secondary outcome revealed that there were no significant differences between the two groups in total HAMD-17 and its sleep factor scores (p &gt; 0.05) at 1, 2, 4, and 6 weeks after treatment initiation. The incidences of adverse events were not significantly different between the two groups (all p &gt; 0.05).Conclusion:C. militaris at the current dose and duration did not improve sleep symptoms in patients with depression, but it is safe with rare side effects.

Effects of electroacupuncture therapy for depression: study protocol for a multi-centered, randomized controlled trial

2019 ◽  
Author(s):  
Wa Cai ◽  
Wen Ma ◽  
Ai-Wen Chen ◽  
Wei-Dong Shen
Keyword(s):  
Randomized Controlled Trial ◽  
Western Medicine ◽  
Negative Impact ◽  
Controlled Trial ◽  
Depression Scale ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Randomized Controlled

Abstract Background As a major public health problem, depression has a negative impact on individuals and society. The aim of this well-designed trial is to evaluate the efficacy and safety of electroacupuncture (EA) treatment for depression. Methods/Design A three-arm parallel, non-blinded, randomized controlled trial was performed in four hospitals (centers). 144 participants will be divided into three groups: electroacupuncture (EA) group, hand acupuncture (HA) group and western medicine group. Participants in EA group and HA group received 12 sessions of acupuncture treatment for 4 weeks. Participants allocated to western medicine group will only take 20mg fluoxetine orally per day for 4 weeks. The primary outcome is Hamilton Depression Scale (HAMD). Secondary outcomes are Self-Rating Depression Scale (SDS), Depression Scale of traditional Chinese medicine (Depression Scale of TCM), brain fMRI and blood biomarkers including neurotransmitters 5-HT, DA, NE, inflammatory cytokines IL-1β, TNF-α, IL-6 and neurotrophin BDNF. All the outcomes will be assessed at baseline, 4 weeks after EA treatment onset and 6-month follow-up. Discussion The results of this trial will verify the efficacy and safety of EA treatment for depressive patients and provide acupuncturists and clinicians with robust clinical evidence.

Incidence of depression and its influencing factors in 387 patients with asthma from Xinjiang, China

2020 ◽  
Vol 41 (2) ◽  
pp. e45-e53 ◽  
Author(s):  
Dilinuer Wufuer ◽  
Haidiya Aierken ◽  
Yan Fang ◽  
Mihereguli Simayi ◽  
Kelibiena Tuerxun ◽  
...  
Keyword(s):  
Risk Factors ◽  
Regression Analysis ◽  
Depression Scale ◽  
High Morbidity ◽  
Hamilton Depression Scale ◽  
Multiple Factors ◽  
Asthma Symptoms ◽  
Depression Status ◽  
Treatment Of Depression ◽  
Quality Life

Background: Our study aimed to investigate the incidence of depression in 387 patients with asthma. Methods: The Zung self-rating depression scale and the Hamilton depression scale were used to evaluate the depression status in patients with asthma. Results: Results of logistic regression analysis indicated that, severity of asthma symptoms, taking medicine, frequency of asthma onset, and lack of education were the major risk factors for depression in patients with asthma. Conclusion: Depression is a complication with high morbidity in patients with asthma. It largely affects disease control of asthma and the quality life in patients. Multiple factors are relevant for depression in the patient with asthma. This study provided a comprehensive horizon for clinical management and treatment of depression in patients with asthma.

The Effect of STH Hypersecretion on Neuro-psychic Function

2019 ◽  
Vol 70 (6) ◽  
pp. 2225-2228
Author(s):  
Bogdan Virgil Cotoi ◽  
Nikolaos Mavritsakis ◽  
Anca Ganescu ◽  
Elena Ionescu
Keyword(s):  
Clinical Trials ◽  
Depression Scale ◽  
Endocrine Disorders ◽  
Hamilton Depression Scale ◽  
Pituitary Dysfunction ◽  
Upper Limit ◽  
Manic Depressive ◽  
Psychic Disorders ◽  
Psychological Examination ◽  
Psychic Function

C: I: Parhon and his colleagues have drawn attention to the existence of psychic disorders, especially manic-depressive and delusional, in a range of endocrine disorders such as acromegaly, gigantism, adipose-genital dystrophy, highlighting the aggressiveness of patients with acromegaly. A number of clinical trials have shown that pituitary dysfunction can be associated with schizophrenia and even epilepsy. In this study, 19 patients were diagnosed with acromegaly following STH dosing, resulting in values higher than the upper limit (ie above 5 ng / mL in men or over 10 ng / mL in females). These patients had complete neurological examination, electroencephalogram, psychological examination, and the Hamilton depression scale.

Sign in / Sign up

Export Citation Format

Share Document